C1酯酶抑制劑市場規模、佔有率和成長分析：按產品來源、適應症、給藥途徑、最終用戶和地區分類－2026-2033年產業預測

2024 年全球 C1 酯酶抑制劑市值為 100 億美元，預計從 2025 年的 119 億美元成長到 2033 年的 478.5 億美元，預測期（2026-2033 年）複合年成長率為 19.0%。

全球C1酯酶抑制劑市場專注於提供血漿衍生和重組療法，用於治療補體和緩激肽介導的血管性水腫，尤其是遺傳性血管性水腫。該領域在預防危及生命的緊急情況和透過及時治療來提高患者生產力方面發揮著至關重要的作用，從而帶來顯著的臨床和經濟效益。該市場已從少數醫院的血漿輸注發展到如今涵蓋多種靜脈和皮下療法，用於治療急性發作和長期預防，例如Berinert、Cinryze、Haegarda和重組Ruconest等產品。市場成長的關鍵促進因素包括診斷技術的進步、監管支持的加強以及基因檢測準確性的提高。這些因素正在擴大已確診患者群體，並推動對治療方法的需求。人工智慧正在提高診斷準確性並輔助治療決策，從而實現個人化護理，並最終提高市場效率和患者療效。

全球C1酯酶抑制劑市場成長要素

醫療專業人員和患者對C1酯酶抑制劑療法的認知度不斷提高，推動了其在適當適應症中的應用範圍擴大，從而增加了市場需求。治療通訊協定的改進和臨床醫生對該療法理解的加深，增強了他們開立此類生物製藥在醫療機構的應用。因此，採購流程更加高效，醫療系統也被鼓勵將這些治療方法納入其藥品清單。這種應用範圍的擴大在市場上形成良性循環，激勵生產商增加供應並增加研發投入。

全球C1酯酶抑制劑市場的限制因素

全球C1酯酶抑制劑市場面臨許多限制因素，主要在於此類治療方法的初始治療費用和持續治療費用高。這種經濟負擔不僅限制了醫療服務提供者、保險公司和病患的用藥途徑，也影響了納入處方藥目錄。預算限制往往導致醫療機構優先選擇更具成本效益的治療方法，使得C1酯酶抑制劑的使用僅限於特定患者群體，阻礙了其廣泛應用，即便處方行為的改變和臨床需求已被認可。此外，這些經濟挑戰也使得小規模的醫療機構在提供此類產品時猶豫不決，並採取謹慎的報銷策略，最終阻礙了市場成長和擴張。

全球C1酯酶抑制劑市場趨勢

全球C1酯酶抑制劑市場正經歷著向重組製劑和皮下注射製劑的顯著轉變，這提高了治療的便利性並擴大了患者的用藥範圍。製劑穩定性、給藥柔軟性和先進遞送技術的創新，使得門診和居家治療成為可能，這與日益重視以患者為中心的醫療模式相契合。這一趨勢促進了生物技術公司和醫療設備製造商之間的策略合作，推動了下一代產品的快速研發。此外，醫療保險公司和醫療服務提供者越來越重視那些能夠減輕醫療機構負擔並提高患者依從性的治療方法，從而促進了持續創新，支持永續的治療模式和強勁的市場成長。

目錄

介紹

• 調查目的
• 市場定義和範圍

調查方法

• 研究過程
• 二級資料和一級資料的方法
• 市場規模估算方法

執行摘要

• 全球市場展望
• 市場主要亮點
• 細分市場概覽
• 競爭環境概述

市場動態及展望

• 總體經濟指標
• 促進者和機會
• 抑制因素和挑戰
• 供給面趨勢
• 需求面趨勢
• 波特的分析和影響

關鍵市場分析

• 關鍵成功因素
• 影響市場的因素
• 主要投資機會
• 生態系測繪
• 2025年市場魅力指數
• PESTLE分析
• 監理情勢

全球C1酯酶抑制劑市場規模：依產品來源分類

• 血漿來源的C1-INH
• 重組C1-INH

全球C1酯酶抑制劑市場規模：依適應症分類

• 預防遺傳性血管性水腫（HAE）
• 急性 HAE 發作

全球C1酯酶抑制劑市場規模：依給藥途徑分類

• 靜脈注射
• 皮下注射

全球C1酯酶抑制劑市場規模：依最終用戶分類

• 專業免疫診所
• 醫院環境
• 家庭醫療保健

全球C1酯酶抑制劑市場規模：按地區分類

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太國家
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲國家

競爭資訊

• 前五大公司對比
• 主要企業2025年的市場定位
• 主要市場公司採取的策略
• 近期市場趨勢
• 企業市場占有率分析，2025 年
• 主要企業的完整公司簡介
  • 公司詳情
  • 產品系列分析
  • 按細分市場進行企業市佔率分析
  • 銷售收入年比比較（2023-2025 年）

主要企業簡介

• CSL Behring
• Grifols
• Shire Pharmaceuticals
• Takeda Pharmaceuticals
• BioMarin Pharmaceutical
• Sobi
• Octapharma
• Genentech
• Apellis Pharmaceuticals
• AbbVie
• Alnylam Pharmaceuticals
• Ionis Pharmaceuticals
• Amgen
• Vertex Pharmaceuticals
• Regeneron Pharmaceuticals
• Sanofi
• Eiger BioPharmaceuticals
• Catalyst Pharmaceuticals
• Emergent BioSolutions
• Pfizer

結論與建議

Global C1 Esterase Inhibitor Market size was valued at USD 10.0 Billion in 2024 and is poised to grow from USD 11.9 Billion in 2025 to USD 47.85 Billion by 2033, growing at a CAGR of 19.0% during the forecast period (2026-2033).

The global C1 esterase inhibitor market focuses on providing plasma-derived and recombinant therapies to manage complement and bradykinin-mediated angioedema, particularly hereditary angioedema. This sector plays a crucial role in preventing life-threatening events and enhancing patient productivity through timely treatments, resulting in significant clinical and economic advantages. The market has evolved from limited hospital-based plasma infusions to a range of intravenous and subcutaneous therapies for both acute episodes and long-term prevention, illustrated by products such as Berinert, Cinryze, Haegarda, and recombinant Ruconest. Key drivers of market growth include advancements in diagnosis, increased regulatory support, and rising genetic testing accuracy, which boost identified patient populations and promote demand for therapies. AI facilitates personalized patient care by improving diagnostic accuracy and guiding treatment decisions, ultimately enhancing market efficiency and patient outcomes.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global C1 Esterase Inhibitor market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global C1 Esterase Inhibitor Market Segments Analysis

Global c1 esterase inhibitor market is segmented by product source, indication, route of administration, end-user and region. Based on product source, the market is segmented into Plasma-derived C1-INH and Recombinant C1-INH. Based on indication, the market is segmented into Prophylaxis of Hereditary Angioedema (HAE) and Acute HAE Attacks. Based on route of administration, the market is segmented into Intravenous (IV) Injection and Subcutaneous (SC) Injection. Based on end-user, the market is segmented into Specialized Immunology Clinics, Hospital Settings and Home Healthcare. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global C1 Esterase Inhibitor Market

The increasing recognition of C1 esterase inhibitor therapies among healthcare practitioners and patients is driving their broader use for suitable indications, thereby enhancing demand. Improved treatment protocols and greater familiarity among clinicians lead to more confidence in prescribing these biologic therapeutics. Additionally, supportive guidelines and educational efforts facilitate the integration of these therapies into healthcare practices. Consequently, procurement processes become more streamlined, prompting healthcare systems to include these treatments in their formularies. This growing adoption encourages manufacturers to increase supply and invest in further advancements, creating a positive feedback loop within the market.

Restraints in the Global C1 Esterase Inhibitor Market

The global C1 Esterase Inhibitor market faces significant constraints due to the high acquisition and continuous treatment costs associated with these therapies. Such financial burdens restrict access for healthcare providers, payers, and patients, while also influencing formulary placements. Budget limitations often lead institutions to favor more cost-effective treatments, resulting in the narrowed use of C1 esterase inhibitors to select patient populations, thereby altering prescribing behaviors and hindering widespread adoption even when clinical necessity exists. Additionally, these economic challenges deter smaller healthcare providers from offering these products and foster cautious reimbursement strategies, ultimately stifling growth and market expansion.

Market Trends of the Global C1 Esterase Inhibitor Market

The Global C1 Esterase Inhibitor market is witnessing a significant shift towards recombinant and subcutaneous formulations, enhancing treatment ease and expanding patient access. Innovations in formulation stability, dosing flexibility, and advanced delivery technologies are enabling outpatient and home treatment options, aligning with the growing preference for patient-centered care. This trend is fostering strategic collaborations between biotechnology firms and device manufacturers, facilitating the rapid development of next-generation products. Additionally, healthcare payers and providers are increasingly favoring therapies that alleviate the burden on care settings while improving patient adherence, thereby stimulating ongoing innovation that supports sustainable treatment models and robust market growth.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global C1 Esterase inhibitor Market Size by Product Source & CAGR (2026-2033)

• Market Overview
• Plasma-derived C1-INH
• Recombinant C1-INH

Global C1 Esterase inhibitor Market Size by Indication & CAGR (2026-2033)

• Market Overview
• Prophylaxis of Hereditary Angioedema (HAE)
• Acute HAE Attacks

Global C1 Esterase inhibitor Market Size by Route of Administration & CAGR (2026-2033)

• Market Overview
• Intravenous (IV) Injection
• Subcutaneous (SC) Injection

Global C1 Esterase inhibitor Market Size by End-User & CAGR (2026-2033)

• Market Overview
• Specialized Immunology Clinics
• Hospital Settings
• Home Healthcare

Global C1 Esterase inhibitor Market Size & CAGR (2026-2033)

• North America (Product Source, Indication, Route of Administration, End-User)
  • US
  • Canada
• Europe (Product Source, Indication, Route of Administration, End-User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product Source, Indication, Route of Administration, End-User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product Source, Indication, Route of Administration, End-User)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product Source, Indication, Route of Administration, End-User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• CSL Behring
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Grifols
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Shire Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BioMarin Pharmaceutical
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sobi
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Octapharma
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Genentech
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Apellis Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alnylam Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ionis Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Vertex Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Regeneron Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eiger BioPharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Catalyst Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Emergent BioSolutions
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations